drugset / Trial / NCT01580813
Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes
Completed
13 enrolled
University of Colorado, Denver
Pfizer · collabUS Department of Veterans Affairs · collab
RandomizedCrossoverDouble-blindTreatment
Summary
People who are overweight or who have type 2 diabetes mellitus (T2DM) have higher levels of certain fats in their blood. The blood vessels and heart of most of these individuals do not work normally and people with T2DM also have an impaired ability to perform exercise. The purpose of this study is to use the free fatty acid lowering drug, acipimox, to temporarily decrease the level of fat in the bloodstream of people with T2DM and observe the physiological changes to blood vessel function and exercise capacity and insulin sensitivity. This will help the investigators to understand ways of improving blood vessel function and the ability to exercise effectively in people who are overweight or have T2DM.
Timeline
- Start
- 2011-06
- Primary completion
- 2015-06-05
- Completion
- 2015-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acipimox | Small molecule | 250 mg | Oral |